can glp 1 cause cancer Risk of pancreatic associated with GLP-1 receptor agonist therapy Research Reveals Potential Risks of
Description
The STEP 4 trial, which specifically examined semaglutide withdrawal, showed that participants who stopped the medication regained 6.9% of body weight over 48 weeks, while those who continued treatment lost an additional 7.9%
Importantly, this decision applied only to the obesity indication ( 7 , 8 )
Despite the encouraging findings, both research teams emphasize that the evidence remains preliminary
Together, these steps support better glycaemic control and contribute to improved metabolic outcomes
The results of the Hargreaves test demonstrated a reduction in pain sensitivity (Fig
